Daily administration of GcMAF is able to slow down solid tumour growth (4ng/kg/4 days).At higher doses, GcMAF causes tumour regression (4ng/kg/day).The injections were into the body cavity (similar to IV in humans).The data suggests that GcMAF prevents the growth of blood supplies to tumours, and stimulates the macrophages to attack both the outside and the tumour cell compartment of a cancer.
We have isolated a selectively deglycosylated form of vitamin D binding protein (DBP-maf) generated from systemically available DBP by a human pancreatic cancer cell line. DBP-maf is antiproliferative for endothelial cells and antiangiogenic in the chorioallantoic membrane assay. DBP-maf administered daily was able to potently inhibit the growth of human pancreatic cancer in immune compromised mice (T/C=0.09). At higher doses, DBP-maf caused tumor regression. Histological examination revealed that treated tumors had a higher number of infiltrating macrophages as well as reduced microvessel density, and increased levels of apoptosis relative to untreated tumors. Taken together, these data suggest that DBP-maf is an antiangiogenic molecule that can act directly on endothelium as well as stimulate macrophages to attack both the endothelial and tumor cell compartment of a growing malignancy.